Everyday foundations · Research Analysis

The MIND diet trial found no cognitive edge over its active control

Both groups improved while receiving counseling, calorie restriction and weight-loss support. The small between-group cognitive difference was not statistically significant, and MRI measures were similar.

Reviewed under standing publication authorization

Discovery, counterevidence, claim mapping, identifiers, funding, correction state and prose were reviewed before release.

Evidence box

Randomized null result against an active dietary control

Study type
Randomized controlled dietary trial
Studied in
Adults age 65+ without cognitive impairment who had family dementia history, BMI above 25 and a suboptimal diet
Participants / sample
604 randomized; 93.4% completed the three-year trial
Publication status
Peer-reviewed primary reports and current registry records; correction status checked August 2, 2026
Outcome type
Global cognition and structural MRI measures over three years
Development stage
Completed human dietary trial; not a demonstrated dementia-prevention treatment
Conflicts / funding
National Institute on Aging; investigators disclosed donated foods and product support
Our assessment
No detected cognitive or MRI advantage over the active control; dementia, healthspan and lifespan were not tested
Reporting confidence
High for the randomized comparison; low for claims beyond the measured endpoints

Start here

Key takeaways

  • Global cognition changed by +0.205 standard units with MIND and +0.170 with control; the adjusted difference was 0.035 (95% CI −0.022 to 0.092; p=.23).
  • Both groups received counseling, a 250-kcal-per-day restriction goal and weight-loss support.
  • MRI measures were similar; the trial did not test dementia prevention or lifespan.

Keep the outcomes separate

What we know / what we do not know

What we know

  • The randomized trial did not detect a significant three-year cognitive advantage for MIND over its active control.
  • Retention was high, and both groups lost weight and improved their diet scores.

What we do not know

  • Whether a different population, adherence level, duration or comparator would yield a different result.
  • Whether the diet prevents dementia, preserves independence, changes mortality, or extends life.

Evidence at a glance

The answer changes with the outcome.

Rows preserve outcome boundaries; they are not a score, ranking, or recommendation.

Evidence by outcome
OutcomeResultBoundary
Global cognitionDifference 0.035 standardized units (95% CI −0.022 to 0.092; p=.23).No significant advantage over the active control.
MRI structureWhite-matter, hippocampal and total gray/white-matter measures were similar.A structural scan is not dementia incidence or daily function.
Dementia and lifespanNot tested.Observational associations cannot substitute for this randomized endpoint.
01

The bottom line

The three-year MIND diet trial did not find a statistically significant cognitive advantage over an active control. Global cognition improved in both groups; the adjusted between-group difference was 0.035 standardized units (95% CI −0.022 to 0.092; p=.23). MRI measures were also similar.

02

Why this matters

Observational studies have linked MIND-style eating patterns with better cognitive outcomes. A randomized test asks a harder question: did assignment to the MIND program outperform the comparison program? Here, that answer was no detected difference—not proof that diet never matters.

03

What researchers did

The trial enrolled 604 older adults without cognitive impairment but with family dementia history, overweight status and a suboptimal diet. Both groups received regular counseling, a 250-kcal-per-day restriction goal and weight-loss support. The contrast was MIND versus another active diet program, not diet change versus doing nothing.

04

What they found

Three-year global-cognition change was +0.205 standardized units with MIND and +0.170 with control. The confidence interval crossed zero. White-matter hyperintensity volume, hippocampal volume and total gray and white matter were similar. Adverse-event burden was reported as similar.

05

How strong is the evidence?

Randomization, a prespecified comparison and high completion support the primary result. The active comparator may have reduced the contrast between groups, but that feature is part of the question the trial actually answered. Post-hoc adherence analyses cannot overwrite the randomized comparison.

06

What this study does not show

The trial did not test dementia prevention, independence, biological-age reversal, healthspan or lifespan. A null result also does not prove that no version of the dietary pattern can affect cognition in any population.

07

Safety, interpretation, and funding

Dietary patterns interact with weight, nutritional needs, medications and medical conditions. The trial was funded by the National Institute on Aging and disclosed donated foods and product support. This evidence summary is not individualized dietary advice.

08

What happens next

Future trials can test longer follow-up, clinical dementia and function outcomes, different comparators, and whether prespecified adherence strategies change the randomized effect without relying on post-hoc selection.

Primary sources

Sources, roles and limits

  1. Barnes et al., randomized MIND diet trial
    Identifier
    PMID:37466280 · PMCID:PMC10513737 · DOI:10.1056/NEJMoa2302368 · NCT02817074
    Role
    Primary randomized null evidence
    Limitation
    Active calorie-restricted comparator; cognition and MRI, not dementia or lifespan.
  2. Open full-text trial report
    Identifier
    PMCID:PMC10513737 · DOI:10.1056/NEJMoa2302368
    Role
    Full methods, results, MRI, adverse-event, funding and disclosure verification
    Limitation
    This is the same primary trial report, not independent replication.
  3. ClinicalTrials.gov record
    Identifier
    NCT02817074
    Role
    Registry identity and study history
    Limitation
    Registration is not government validation of safety or efficacy.

Connected topics

Continue through the knowledge system

Intervention categoriesStudy and trial recordsHow evidence differsEveryday foundations stories

Continue with real coverage

Keep reading

These are learning paths, not rankings, recommendations, or evidence that the stories support one another.

Another cognitive-aging question without a dementia endpoint

Research AnalysisHealth & function

Multivitamins moved some tests and aging clocks. What does that mean?

COSMOS found small cognitive-test differences and modest movement in two DNA-methylation clocks; neither establishes dementia prevention or longer life.

Evidence scopeHuman cognitive tests and biomarkers · correlated randomized substudies

Disclosures and history

  • August 2, 2026 — source discovery, verification and counterevidence completed before prose drafting.
  • August 2, 2026 — atomic claim map, article draft, identifiers, funding, correction state and inference boundaries reviewed.
  • Corrections: none identified for the MIND randomized report or registry record as of publication.